Improving efficacy of glycoconjugate vaccines: from chemical conjugates to next generation constructs

Avery, 1929, Chemo-immunological studies on conjugated carbohydrate-proteins: II. Immunological specificity of synthetic of sugar-protein antigens, J Exp Med, 50, 533, 10.1084/jem.50.4.533 Macleod, 1945, Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides, J Exp Med, 82, 445, 10.1084/jem.82.6.445 Baker, 2018, Technologies to address antimicrobial resistance, Proc Natl Acad Sci U S A, 115, 12887, 10.1073/pnas.1717160115 Parke, 1987, Capsular polysaccharide of Haemophilus influenzae type b as a vaccine, Pediatr Infect Dis J, 6, 795, 10.1097/00006454-198708000-00040 Peltola, 1977, Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland, Pediatrics, 60, 730, 10.1542/peds.60.5.730 Peltola, 1977, Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age, N Engl J Med, 297, 686, 10.1056/NEJM197709292971302 Steinhoff, 1981, Group C Neisseria meningitidis variant polysaccharide vaccines in children, Infect Immun, 34, 144, 10.1128/IAI.34.1.144-146.1981 Costantino, 1992, Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C, Vaccine, 10, 691, 10.1016/0264-410X(92)90091-W Obaro, 2002, The new pneumococcal vaccine, Clin Microbiol Infect, 8, 623, 10.1046/j.1469-0691.2002.00424.x Costantino, 2011, The design of semi-synthetic and synthetic glycoconjugate vaccines, Expert Opin Drug Discov, 6, 1045, 10.1517/17460441.2011.609554 Micoli, 2018, Potential targets for next generation anti-microbial glycoconjugate vaccines, FEMS Microbiol Rev, 42, 388, 10.1093/femsre/fuy011 Micoli, 2018, Protein carriers for glycoconjugate vaccines: history, selection criteria, characterization and new trends, Molecules, 23, 10.3390/molecules23061451 Dagan, 2010, Glycoconjugate vaccines and immune interference: a review, Vaccine, 28, 5513, 10.1016/j.vaccine.2010.06.026 Verez-Bencomo, 2004, A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b, Science, 305, 522, 10.1126/science.1095209 van der Put, 2016, A synthetic carbohydrate conjugate vaccine candidate against shigellosis: improved bioconjugation and impact of alum on immunogenicity, Bioconjug Chem, 27, 883, 10.1021/acs.bioconjchem.5b00617 Hatz, 2015, Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: a single blind, partially randomized phase I study, Vaccine, 33, 4594, 10.1016/j.vaccine.2015.06.102 Riddle, 2016, Safety and immunogenicity of a candidate bioconjugate caccine against Shigella flexneri 2a administered to healthy adults: a single-blind, randomized phase I study, Clin Vaccine Immunol, 23, 908, 10.1128/CVI.00224-16 Launay, 2017, Safety profile and immunologic responses of a novel vaccine against Shigella sonnei administered intramuscularly, intradermally and intranasally: results from two parallel randomized phase 1 clinical studies in healthy adult volunteers in Europe, EBioMedicine, 22, 164, 10.1016/j.ebiom.2017.07.013 Obiero, 2017, A phase 2a randomized study to evaluate the safety and immunogenicity of the 1790GAHB generalized modules for membrane antigen vaccine against Shigella sonnei administered intramuscularly to adults from a ahigellosis-endemic country, Front Immunol, 8, 1884, 10.3389/fimmu.2017.01884 Rappuoli, 2019, On the mechanisms of conjugate vaccines, Proc Natl Acad Sci U S A, 116, 14, 10.1073/pnas.1819612116 Rappuoli, 2018, Glycoconjugate vaccines: principles and mechanisms, Sci Transl Med, 10, 10.1126/scitranslmed.aat4615 Rappuoli, 2011, A sweet T cell response, Nat Med, 17, 1551, 10.1038/nm.2587 Sun, 2019, Polysaccharide structure dictates mechanism of adaptive immune response to glycoconjugate vaccines, Proc Natl Acad Sci U S A, 116, 193, 10.1073/pnas.1816401115 Micoli, 2019, Glycoconjugate vaccines: current approaches towards faster vaccine design, Expert Rev Vaccines, 1 Hu, 2016, Towards the next generation of biomedicines by site-selective conjugation, Chem Soc Rev, 45, 1691, 10.1039/C4CS00388H Italia, 2018, Resurrecting the bacterial tyrosyl-tRNA synthetase/tRNA pair for expanding the genetic code of both E. coli and eukaryotes, Cell Chem Biol, 25, 1304, 10.1016/j.chembiol.2018.07.002 Zhang, 2013, Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunity, Proc Natl Acad Sci U S A, 110, 13564, 10.1073/pnas.1307228110 Wen, 2018, Toward automated enzymatic synthesis of oligosaccharides, Chem Rev, 118, 8151, 10.1021/acs.chemrev.8b00066 Gao, 2013, Immunoactivity of protein conjugates of carba analogues from Neisseria meningitidis a capsular polysaccharide, ACS Chem Biol, 8, 2561, 10.1021/cb400463u https://vaxxilon.com/wp-content/uploads/2019/06/Haemophilus_influenzae_type_B.pdf. Carboni, 2017, Structure of a protective epitope of group B Streptococcus type III capsular polysaccharide, Proc Natl Acad Sci U S A, 114, 5017, 10.1073/pnas.1701885114 Safari, 2012, Gold nanoparticles as carriers for a synthetic Streptococcus pneumoniae type 14 conjugate vaccine, Nanomedicine, 7, 651, 10.2217/nnm.11.151 Wacker, 2002, N-Linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli, Science, 298, 1790, 10.1126/science.298.5599.1790 Kay, 2019, Recent advances in the production of recombinant glycoconjugate vaccines, NPJ Vaccines, 4, 16, 10.1038/s41541-019-0110-z Harding, 2019, Glycoengineering bioconjugate vaccines, therapeutics, and diagnostics in E. coli, Glycobiology, 29, 519, 10.1093/glycob/cwz031 Harding, 2019, A platform for glycoengineering a polyvalent pneumococcal bioconjugate vaccine using E. coli as a host, Nat Commun, 10, 10.1038/s41467-019-08869-9 Feldman, 2019, A promising bioconjugate vaccine against hypervirulent Klebsiella pneumoniae, Proc Natl Acad Sci U S A, 116, 18655, 10.1073/pnas.1907833116 Wacker, 2014, Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli, J Infect Dis, 209, 1551, 10.1093/infdis/jit800 Gerke, 2015, Production of a Shigella sonnei vaccine based on generalized modules for membrane antigens (GMMA), 1790GAHB, PLoS One, 10, 10.1371/journal.pone.0134478 Rossi, 2014, Modulation of endotoxicity of Shigella generalized modules for membrane antigens (GMMA) by genetic lipid A modifications: relative activation of TLR4 and TLR2 pathways in different mutants, J Biol Chem, 289, 24922, 10.1074/jbc.M114.566570 Rossi, 2016, Toll-like receptor activation by generalized modules for membrane antigens from Lipid A mutants of Salmonella enterica serovars Typhimurium and Enteritidis, Clin Vaccine Immunol, 23, 304, 10.1128/CVI.00023-16 Schager, 2018, IgG responses to porins and lipopolysaccharide within an outer membrane-based vaccine against nontyphoidal Salmonella develop at discordant rates, mBio, 9, 10.1128/mBio.02379-17 De Benedetto, 2017, Characterization of O-antigen delivered by generalized modules for membrane antigens (GMMA) vaccine candidates against nontyphoidal Salmonella, Vaccine, 35, 419, 10.1016/j.vaccine.2016.11.089 Micoli, 2018, Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella, Proc Natl Acad Sci U S A, 41, 10428, 10.1073/pnas.1807655115 Kis, 2019, Emerging technologies for low-cost, rapid vaccine manufacture, Biotechnol J, 14, 10.1002/biot.201970055 Gerritzen, 2017, Bioengineering bacterial outer membrane vesicles as vaccine platform, Biotechnol Adv, 35, 565, 10.1016/j.biotechadv.2017.05.003 Chen, 2016, Outer membrane vesicles displaying engineered glycotopes elicit protective antibodies, Proc Natl Acad Sci U S A, 113, E3609, 10.1073/pnas.1518311113 Valguarnera, 2017, Glycoengineered outer membrane vesicles as a platform for vaccine development, Meth Enzymol, 597, 285, 10.1016/bs.mie.2017.06.032 Stevenson, 2018, Immunization with outer membrane vesicles displaying conserved surface polysaccharide antigen elicits broadly antimicrobial antibodies, Proc Natl Acad Sci U S A, 115, E3106, 10.1073/pnas.1718341115